Record revenue but margin pressure; pharma surge justified

₹300.5 Cr delivered; validates milestone claim

Gross margin fell 5.3pp QoQ (46.6%→41.3%) despite +26.3% QoQ revenue; EBITDA gain mainly from consolidation, not pricing

₹46.7 inflated by lube -17% volume mix; MD acknowledges normalizing to ₹44-45 as lubes/Qpack recover

Q1 ₹8-9 Cr at 41% YoY; quarterly run-rate ₹11-12 Cr (extrapolated MD guidance); on track

Q1 only 6% (lube -17% offset by pharma +38%, food +24%); materially below target YTD

Prior ₹42.5-43 → now ₹44-45 full year (Q1 ₹46.7 is peak). MD credibly attributed to permanent consolidation/efficiencies, not one-off.

Prior ₹80-85 Cr guidance → now ₹90 Cr (₹25-30 Cr for pharma/device expansion). Still down from prior-year actual ₹130-135 Cr.

Still ₹50-55 Cr (50% growth). Q1 ₹8-9 Cr at 41% YoY supports trajectory. No change, but confidence high given order pipeline (20-25 active, 10 more visiting).

Q1 only 6% (vs 10-13% prior guidance). Lube -17%, Qpack +2% offset pharma +38%, food +24%. MD still targeting 10-12%, but trajectory is weak.

Will normalize to ₹44-45 as lube recovers and capacity utilization improves. Q2/Q3 last year were below ₹40. Consolidation benefits are long-term and permanent.

EBITDA per kg up 12%, proving efficiency and consolidation gains. Revenue looks high due to inflationary RM prices which we collected. Proof is EBITDA growth of ₹6/kg.

Price-sensitive segment. Edible oil/cashew industry hesitant when RM jumped ₹100→₹150. New facilities in North and South (Cheyyar) now adding numbers; expect double-digit growth next quarters.

Dosing pens: ₹25-30 Cr capex, 1-3 year development (1 year with IP partner). Semiconductor trays: very long shot, early stage. Current facility expansion for ophthalmic (25k sq ft, 6 months to completion).

Yes. Asian Paints IML share rising, strong growth for us this quarter. Expect 10-15% paint volume growth full year if war resolves. Sticky customer base switching back to MTPL.

6% is depressed by 17% lube decline. Without lube, would be 9%. Pharma +38% (weight-light), food +24%, paint +11%. Lube recovery + Qpack normalization will drive 10%+ in remaining quarters.

RM cost elevated (₹145 now vs ₹155 peak). Working capital may stabilize but not decrease much. If war worsens, could spike; if resolved, could decline 5-10%.

6% volume + ~13% from RM price passthrough. But mix shift (pharma +40%, food +24%) adds another 10-12% value. So ≈15% inflation, ≈4-5% mix benefit in the delta.

20-25 active orders now. 50+ pharma companies listed globally. 10+ more scheduled to visit in next couple of weeks/months. Strong pipeline.

3 products patented, 6 more in pilot stage (2 months to ready). IP and marketing underway. ₹50k mold cost participation from partner. Q3 FY27 commercial launch targeting, ₹2 Cr revenue possible.

Q1 ₹300.5 Cr = 24.9% YoY. Run-rate ₹1.2 Cr annualized if 10%+ growth holds. Conservative target likely beaten.

Q1 ₹46.7 is peak due to lube/Qpack mix headwinds. As segments normalize, expect ₹44-45 sustained by consolidation & efficiencies (permanent). Full-year EBITDA growth 19-20% targeted.

Depends on volume recovery and RM stabilization. Consolidation benefits are durable. Gross margin compression is concern but EBITDA per kg offset.

Q1 capex ₹20-22 Cr invested. Plan includes 10-12% annual capacity addition and 25k sq ft ophthalmic facility (6 months to completion).

Gross margin fell 530bp QoQ (46.6%→41.3%) despite 26% revenue growth and claimed RM passthrough. Suggests customers absorbed cost; if RM stays elevated and market softens, margin recovery is at risk.

Q1 volume +6% vs 10-13% prior guidance. Lube -17% (war/Iran base oil) is temporary, but Qpack +2% (price sensitivity, de-stocking) may be structural. Without lube recovery, full-year 10-12% target unachievable.

Working capital jumped ₹15 Cr to ₹125 Cr due to 35% YoY RM cost inflation. Finance cost up 20% QoQ. If RM stays elevated, interest burden could offset operational margin gains. Liquidity is manageable but stretched.

Pharma/device capex ₹25-30 Cr (part of ₹90 Cr total). Dosing pens timeline 1-3 years (hopes for 1 year with IP partner, but not confirmed). Ophthalmic molds need 5-6 more months. Semiconductor trays are 'very long shot'. Heavy bet on uncertain timeline.

Pharma is now 3.5% of revenue but targeting ₹50-55 Cr (14-18% of FY27 revenue). Q1 showed 41% growth and 20-25 active customers with 10+ pipeline. But scale-up risk is real: manufacturing quality, regulatory compliance, customer concentration.